Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible.
AML-MRC
CPX-351
hematopoeietic stem cell transplantation
induction therapy
prognosis
therapy-related acute myeloid leukemia
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
06
2020
accepted:
04
08
2020
entrez:
12
10
2020
pubmed:
13
10
2020
medline:
13
10
2020
Statut:
epublish
Résumé
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and treatment-related acute myeloid leukemia (tAML) after chemotherapy or radiation therapy for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the cases of four consecutive patients with AML-MRC or tAML who received CPX-351 as outpatient induction therapy immediately followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in complete remission and one in partial remission) and two patients received allo-HSCT in aplasia (one at 11 days and one at 52 days after the start of induction therapy with CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are alive and two are in remission. Further studies will help define and expand the role of CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to undergo allo-HSCT.
Identifiants
pubmed: 33042819
doi: 10.3389/fonc.2020.01746
pmc: PMC7526474
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1746Informations de copyright
Copyright © 2020 Vucinic, Jentzsch, Schwind, Bach, Leiblein, Remane, Rieprecht, Otto, Kubasch, Behre, Cross, Platzbecker and Franke.
Références
Exp Hematol. 2011 Jul;39(7):741-50
pubmed: 21530609
Blood Adv. 2019 Oct 22;3(20):2911-2919
pubmed: 31648312
Leuk Res. 2010 Sep;34(9):1214-23
pubmed: 20138667
Clin Cancer Res. 2019 May 1;25(9):2685-2690
pubmed: 30541745
Blood Adv. 2018 Aug 28;2(16):2127-2135
pubmed: 30143527
Mol Cancer Ther. 2006 Jul;5(7):1854-63
pubmed: 16891472
Blood. 1997 May 1;89(9):3323-9
pubmed: 9129038
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood. 2010 Oct 14;116(15):2742-51
pubmed: 20581309
Blood. 2011 Feb 24;117(8):2307-18
pubmed: 21098397
Leuk Lymphoma. 2020 Mar;61(3):631-640
pubmed: 31760835
Am J Hematol. 2015 Mar;90(3):208-14
pubmed: 25421221
Leuk Res. 2009 Jan;33(1):129-39
pubmed: 18676016
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
J Clin Oncol. 2015 Nov 1;33(31):3641-9
pubmed: 26304885
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 1997 Jun 15;89(12):4531-6
pubmed: 9192777
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269